Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kalvista Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KALV
Nasdaq
8731
https://www.kalvista.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
- Apr 22nd, 2024 10:30 am
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
- Apr 5th, 2024 10:30 pm
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
- Apr 3rd, 2024 10:30 am
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 2nd, 2024 10:30 am
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
- Mar 18th, 2024 10:30 am
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
- Mar 12th, 2024 10:30 am
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
- Mar 11th, 2024 10:30 am
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
- Mar 8th, 2024 11:30 am
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
- Mar 7th, 2024 11:30 am
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
- Mar 6th, 2024 11:30 am
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
- Feb 27th, 2024 11:30 am
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
- Feb 26th, 2024 11:30 am
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
- Feb 20th, 2024 11:30 am
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
- Feb 16th, 2024 11:30 am
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
- Feb 15th, 2024 11:30 am
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Feb 14th, 2024 9:18 pm
UPDATE 1-KalVista meets main goals in late-stage trial for genetic disease
- Feb 13th, 2024 12:10 pm
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
- Feb 13th, 2024 11:30 am
Kalvista pill succeeds in late-stage study for rare swelling disorder
- Feb 13th, 2024 6:30 am
Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ...
- Jan 13th, 2024 8:12 am
Scroll